Diagnostic Tests and Monitoring Strategies for MGUS
Initial Diagnostic Workup
- The diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS) requires serum monoclonal protein <3 g/dl, clonal bone marrow plasma cells <10%, and absence of end-organ damage (CRAB criteria: hypercalcemia, renal insufficiency, anemia, and bone lesions) 1
- Serum protein electrophoresis (SPEP) is used to detect and quantify M-protein 1
- Serum immunofixation electrophoresis (SIFE) is used to characterize heavy and light chains 1
- Quantitative immunoglobulin levels (IgG, IgA, and IgM) are essential for diagnosis 1
- Serum free light chain (FLC) assay with kappa/lambda ratio is a crucial test 1
- Complete blood count is used to rule out anemia 2, 1
- Serum calcium and creatinine are used to assess for end-organ damage 1
- Qualitative test for urine protein, followed by urine protein electrophoresis and immunofixation if positive, is recommended 1
Risk Stratification
- Low-risk MGUS is defined as serum M-protein <15 g/L, IgG type, and normal FLC ratio 1
- Intermediate/high-risk MGUS is defined as serum M-protein >15 g/L, and/or IgA or IgM protein type, and/or abnormal FLC ratio 1
Additional Testing Based on Risk
- Baseline bone marrow examination or skeletal radiography is not routinely indicated for low-risk MGUS 1
- Bone marrow aspirate and biopsy at baseline are recommended to rule out underlying plasma cell malignancy in intermediate/high-risk MGUS 1
- Conventional cytogenetics and fluorescence in situ hybridization (FISH) on bone marrow sample are recommended for intermediate/high-risk MGUS 1
- Plasma cell labeling index and search for circulating plasma cells using flow cytometry are recommended if available 1
- Computed tomography scan of the abdomen is recommended to check for asymptomatic retroperitoneal lymph nodes in IgM MGUS 1
Monitoring Recommendations
- Repeat SPEP is recommended in 6 months after diagnosis for low-risk MGUS 1
- Follow-up every 2-3 years or when symptoms suggestive of plasma cell malignancy arise is recommended for low-risk MGUS 1
- Follow-up with SPEP and complete blood count is recommended in 6 months for intermediate/high-risk MGUS 1
- Annual follow-up is recommended for life for intermediate/high-risk MGUS 1
Important Clinical Considerations
- MGUS must be differentiated from smoldering multiple myeloma (SMM) and symptomatic multiple myeloma 1
- SMM has a higher risk of progression (10% per year over first 5 years) compared to MGUS (1% per year) 2
- Bone marrow examination is always required if a patient with presumed MGUS has unexplained anemia, renal insufficiency, hypercalcemia, bone lesions, or suspicion of AL amyloidosis 1
- Patients should be instructed to contact their physician if there is any change in their clinical condition 1
- Failing to differentiate MGUS from SMM or MM, which have different management approaches, is a common pitfall to avoid 1
- Discontinuing follow-up after a period of stability is not recommended as progression risk continues lifelong 1
- Missing the diagnosis by not performing immunofixation when SPEP is negative or equivocal is a common pitfall to avoid 1
- Initiating treatment for MGUS outside of clinical trials is not recommended 1